<DOC>
	<DOCNO>NCT00002693</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy carboplatin topotecan treating patient chronic myelogenous leukemia recurrent acute leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Chronic Myelogenous Leukemia Recurrent Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Estimate maximum tolerate dose carboplatin plus topotecan give 5-day continuous infusion patient recurrent acute lymphocytic myeloid leukemia accelerate blastic phase chronic myelogenous leukemia . - Assess toxicity regimen patient . - Gather preliminary information activity regimen patient . - Examine pharmacokinetics topotecan administer concurrently carboplatin . OUTLINE : This dose escalation study topotecan . Patients stratify accord prior bone marrow transplant ( BMT ) ( yes v ) . - Induction : Patients receive carboplatin topotecan IV 3 time day day 1-5 . Patients may also receive filgrastim ( G-CSF ) begin day 7 14 . Retreatment base result marrow exam day 10-14 . Patients less 5 % blast undergo second marrow exam upon blood count recovery day 26-30 , whichever earlier . Patients least 5 % blast day 21 receive one course , absence unacceptable toxicity discretion investigator . Patients great 5 % blast begin G-CSF blood count recover , proceed consolidation . Cohorts 1-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients prior BMT enter level 3-6 patient prior BMT tolerate level . - Consolidation ( begin around day 42 last Induction course ) : Patients ALL/AML complete remission ( CR ) CML chronic phase receive 2 additional course ( dos ) 6-8 week apart . Patients experience relapse CR last least 6 month may receive additional treatment . PROJECTED ACCRUAL : A total 15-20 patient without 2-20 patient prior bone marrow transfer accrue study 2-2.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute lymphocytic myeloid leukemia ( ALL AML ) 1 follow category : Failed achieve complete response ( CR ) initial induction regimen First relapse within 1 year initial CR Failed reinduction therapy first relapse Second relapse 2 different induction regimen Relapse define 10 % blast marrow circulate blast peripheral blood either : Symptoms recurrence ( e.g. , B symptom ) Evidence impend marrow failure ( i.e. , cytopenia ) OR Chronic myelogenous leukemia accelerate blastic phase 1 prior induction regimen No HLAidentical sibling marrow donor patient ineligible allogeneic marrow transplantation No clinical symptom CNS leukemia Patients history CNS leukemia must pretreatment lumbar puncture demonstrate absence active CNS disease No active CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 4 week Hematologic : Hepatic : Bilirubin le 2 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No congestive heart failure No poorly control arrhythmia No myocardial infarction within past 3 month Other : No active infection No serious medical condition would prevent compliance Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 24 hour since prior hydroxyurea impend leukostasis No concurrent hydroxyurea glucocorticoid Recovered prior chemotherapy Endocrine therapy : At least 24 hour since prior glucocorticoid impend leukostasis At least 7 day since prior amphotericin aminoglycosides No concurrent glucocorticoid Radiotherapy : Not specify Surgery : Not specify Other : No concurrent aminoglycoside antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>neutropenia</keyword>
</DOC>